98%
921
2 minutes
20
Background: Bullous Pemphigoid (BP) is caused by a predominantly Th2-mediated attack on the basement membrane by the production of anti-BP180 and anti-BP230 antibodies. Malignant tumors can exacerbate immune disorders through a variety of potential pathways, including pro-inflammatory responses in the tumor microenvironment, cross-immune responses induced by tumor-associated antigens, and the lifting of immunosuppressive states and activation of underlying autoimmune responses after surgery. Alopecia Areata (AA) is an autoimmune disease caused by T-lymphocyte-mediated destruction of the immune privilege of the hair follicle, specifically involving the immune axes of Th1, Th2 and Th17. Both AA and BP are associated with dysregulation of cytokines such as IL-4, IL-13, and IL-17. However, the mechanisms underlying the coexistence of the three are unclear, and no cases of their combination have been reported.
Case Presentation: A 67-year-old male patient presented to the clinic complaining of scattered erythema and blisters on the trunk and extremities with marked itching for 4 days. Previously, the patient had undergone surgery for intrahepatic cholangiocarcinoma 10 days earlier. Furthermore, he had developed alopecia areata with the SALT 50 six months earlier and has recovered with white hairs. By combining the patient's history with his laboratory tests and pathologic examinations, the patient was diagnosed with bullous pemphigoid, intrahepatic cholangiocarcinoma, and alopecia areata. The patient demonstrated normalization of serum tumor markers post-resection of intrahepatic cholangiocarcinoma. Bullous pemphigoid lesions resolved completely with dupilumab-targeted therapy, while alopecia areata exhibited spontaneous remission with full hair regrowth despite no disease-specific treatment.
Conclusion: This case report is the first to present the coexistence of bullous pemphigoid, malignant tumors, and alopecia areata, especially since the patient did not undergo immune medication, such as chemotherapy, which has implications for clinical confrontation with the combined presence of these diseases.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12408584 | PMC |
http://dx.doi.org/10.3389/fimmu.2025.1650253 | DOI Listing |
Clin Cosmet Investig Dermatol
September 2025
Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, 100730, People's Rep
Purpose: Alopecia areata (AA) is a common, immune-mediated, non-scarring form of hair loss. Janus kinase inhibitors provide considerable insight into the treatment of severe AA. However, the efficacy and safety of upadacitinib treatment of adolescents and pediatric patients with severe AA is unclear, especially in those without concomitant atopic diseases.
View Article and Find Full Text PDFFront Immunol
September 2025
Department of Dermatology, The National Center for the Integration of Traditional Chinese and Western Medicine, China-Japan Friendship Hospital, Beijing, China.
Background: Bullous Pemphigoid (BP) is caused by a predominantly Th2-mediated attack on the basement membrane by the production of anti-BP180 and anti-BP230 antibodies. Malignant tumors can exacerbate immune disorders through a variety of potential pathways, including pro-inflammatory responses in the tumor microenvironment, cross-immune responses induced by tumor-associated antigens, and the lifting of immunosuppressive states and activation of underlying autoimmune responses after surgery. Alopecia Areata (AA) is an autoimmune disease caused by T-lymphocyte-mediated destruction of the immune privilege of the hair follicle, specifically involving the immune axes of Th1, Th2 and Th17.
View Article and Find Full Text PDFTelemed Rep
August 2025
Medical Center Department of Dermatology, University of Pittsburgh, Wexford, Pennsylvania, USA.
Background: Non-scarring alopecia, including androgenetic alopecia (AGA), alopecia areata (AA), telogen effluvium (TE), and traction alopecia (TA), significantly impacts psychosocial well-being. Access to specialized dermatologic care for these conditions is often limited, particularly in underserved populations. Asynchronous teledermatology has emerged as a potential solution to extend care to these groups.
View Article and Find Full Text PDFJ Dermatolog Treat
December 2025
Department of Dermatology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Objectives: Baricitinib showed efficacy for alopecia areata (AA) in clinical trials, with real-world data supporting its short-term effectiveness. However, long-term data are limited. We assessed the effectiveness and safety of baricitinib in AA patients over one year and explored predictive factors.
View Article and Find Full Text PDFJ Drugs Dermatol
September 2025
Background: Alopecia universalis (AU) is the most severe form of alopecia areata (AA), characterized by complete scalp and body hair loss. While post-COVID-19 hair loss is often attributed to telogen effluvium (TE), emerging evidence suggests that COVID-19 may also trigger AU through immune dysregulation, particularly via interferon-gamma (IFN-γ)-mediated inflammation. The chronic and relapsing nature of AU raises challenges in long-term disease management, particularly regarding treatment duration and relapse prevention.
View Article and Find Full Text PDF